Featured Research

from universities, journals, and other organizations

Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer

Date:
August 28, 2008
Source:
Journal of the National Cancer Institute
Summary:
The use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a reduced risk of basal cell or squamous cell skin cancers in US veterans, researchers report in the Aug. 26 online issue of the Journal of the National Cancer Institute.

The use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was associated with a reduced risk of basal cell or squamous cell skin cancers in U.S. veterans, researchers report in the August 26 online issue of the Journal of the National Cancer Institute.

Related Articles


ACE inhibitors and ARBs are frequently prescribed medications for the treatment of high blood pressure. Data from in vitro cell studies and animal models suggest these drugs may slow tumor growth and inhibit angiogenesis. Additionally, some epidemiological studies in humans suggest that ACE inhibitors and ARBs may reduce the risk of nonmelanoma skin cancers.

To test this possibility more specifically, Jennifer Christian, Pharm.D., Ph.D., of the VA Medical Center and Brown University in Providence, R.I., and colleagues performed a cohort study including 1,051 veterans who were at increased risk of keratinocyte skin cancers, including basal cell carcinoma or squamous cell carcinoma. The participants were already enrolled in a VA Cooperative Studies Program trial aimed at testing the efficacy of a topical agent. The researchers collected data on ACE inhibitor and ARBs use from a Veterans Affairs pharmacy database.

With a median follow-up of 3.4 years, the researchers identified 472 cases of basal cell carcinoma, 309 squamous cell cancers, and 200 deaths in the study population. The group taking either an ACE inhibitor or ARBs had a 39 percent relative reduction in incidence of basal cell cancer and a 33 percent relative reduction in squamous cell cancers compared with nonusers. The absolute incidence of the two cancers together was 237 per 1,000 person-years in the ACE inhibitor or ARB users and 374 per 1,000 among nonusers.

The researchers concluded that the use of these agents was associated with a reduction in the risk of nonmelanoma skin cancers but noted that the exact mechanism of action behind the reduction is unknown. "We were surprised to find such a pronounced reduction in [basal cell carcinoma and squamous cell carcinoma] incidence in users of ACE inhibitors or ARBs in such a high-risk group over a short amount of time," the authors write. "Because individuals at normal risk of keratinocyte cancer were not included in our study, the extent to which the results might apply to such individuals is unknown."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention in the Randomized VATTC Trial. Journal of the National Cancer Institute, 2008; 100:1223-1232 DOI: 10.1093/jnci/djn262

Cite This Page:

Journal of the National Cancer Institute. "Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer." ScienceDaily. ScienceDaily, 28 August 2008. <www.sciencedaily.com/releases/2008/08/080826190854.htm>.
Journal of the National Cancer Institute. (2008, August 28). Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2008/08/080826190854.htm
Journal of the National Cancer Institute. "Angiotensin Inhibitors And Receptor Blockers Linked To Lower Risk Of Nonmelanoma Skin Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/08/080826190854.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins